Alprazolam
- Generic Name
- Alprazolam
- Brand Names
- Niravam, Xanax
- Drug Type
- Small Molecule
- Chemical Formula
- C17H13ClN4
- CAS Number
- 28981-97-7
- Unique Ingredient Identifier
- YU55MQ3IZY
- Background
Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders. It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole. Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse effects are generally related to the sedation it can cause. Alprazolam has been mixed with alcohol as a drug of abuse to potentiate the sedative effects of the drug which may lead to coma and death. Alprazolam was given FDA approval on October 16, 1981.
- Indication
Alprazolam is indicated for the acute treatment of generalized anxiety disorder in adults. Alprazolam is also indicated, either as a standard or extended-release formulation, for the treatment of panic disorder with or without agoraphobia in adults.
Alprazolam may also be prescribed off-label for insomnia, premenstrual syndrome, and depression.
- Associated Conditions
- Generalized Anxiety Disorder, Panic Disorder
Fasting Study of Alprazolam Extended-Release Tablets 1 mg to Xanax XR Tablets 1 mg
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 24
- Registration Number
- NCT00647894
- Locations
- 🇺🇸
Kendle International Inc., Morgantown, West Virginia, United States
A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT00635076
- Locations
- 🇺🇸
Pfizer Investigational Site, Middleton, Wisconsin, United States
A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic Attacks
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT00634790
- Locations
- 🇺🇸
Pfizer Investigational Site, Middleton, Wisconsin, United States
A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic Disorder
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT00635531
- Locations
- 🇺🇸
Pfizer Investigational Site, Middleton, Wisconsin, United States
Staccato Alprazolam Abuse Liability
- Conditions
- Abuse Liability of Staccato Alprazolam
- Interventions
- Drug: Inhaled placebo + oral placeboDrug: Inhaled alprazolam 0.5 mgDrug: Oral alprazolam 4 mDrug: Oral alprazolam 2 mg qualifying sessionDrug: Oral placebo qualifying session
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT00603980
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2014-12-11
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 56
- Registration Number
- NCT00592332
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2009-09-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 47
- Registration Number
- NCT00580190
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 14
- Registration Number
- NCT00574639
- Locations
- 🇺🇸
University of Maryland, Baltimore, Baltimore, Maryland, United States
A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder
- Conditions
- Social Phobia
- Interventions
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 35
- Registration Number
- NCT00555139
- Locations
- 🇪🇸
GSK Investigational Site, Terrassa - Barcelona, Spain
Staccato Alprazolam in Panic Attack
- Conditions
- Treatment of Induced Panic Attack
- Interventions
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Alexza Pharmaceuticals, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT00477451
- Locations
- 🇺🇸
SUNY Downstate Medical Center, Brooklyn, New York, United States
🇺🇸New York State Psychiatric Institute, New York, New York, United States
🇺🇸Mt. Sinai School Of Medicine, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.